Harbert Fund Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Harbert Fund Advisors’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-177,815	Closed	-$1.66M	–	4
2025 Q3	$1.66M	Sell	177,815 -109,799	-38%	-$950K	10.86%	5
2025 Q2	$2.39M	Sell	287,614 -179,255	-38%	-$1.23M	7.16%	6
2025 Q1	$2.84M	Hold	466,869	–	–	3.22%	8
2024 Q4	$2.95M	Hold	466,869	–	–	1.53%	19
2024 Q3	$2.33M	Hold	466,869	–	–	1.38%	26
2024 Q2	$2.85M	Hold	466,869	–	–	2.03%	14
2024 Q1	$5.19M	Hold	466,869	–	–	3.57%	8
2023 Q4	$5.24M	Hold	466,869	–	–	3.59%	8
2023 Q3	$3.51M	Hold	466,869	–	–	2.5%	18
2023 Q2	$4.12M	Hold	466,869	–	–	2.31%	18
2023 Q1	$3.88M	Buy	466,869 +149,920	+47%	+$1.39M	2.57%	13
2022 Q4	$3.04M	Buy	316,949 +127,199	+67%	+$1.13M	2.44%	15
2022 Q3	$1.54M	Hold	189,750	–	–	0.82%	35
2022 Q2	$1.06M	Hold	189,750	–	–	0.52%	35
2022 Q1	$1.06M	Hold	189,750	–	–	0.45%	34
2021 Q4	$835K	Buy	189,750 +15,000	+9%	+$112K	0.21%	38
2021 Q3	$1.65M	Buy	174,750 +53,899	+45%	+$404K	0.58%	29
2021 Q2	$881K	Buy	+120,851	New	+$807K	0.49%	27

Other funds holding FENC

SCA

Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Harbert Fund Advisors's FENC Position: Q4 2025 in Review

Harbert Fund Advisors sold out of Fennec Pharmaceuticals (FENC) in Q4 2025, closing a stake of 177,815 shares — an estimated $1.66M sold.

Harbert Fund Advisors first reported a position in FENC in Q2 2021 and held it in 18 quarters. The position peaked at $5.24M in Q4 2023. 96 funds tracked by Wall St. Rank hold FENC as of Q4 2025.

Harbert Fund Advisors reported no remaining Fennec Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Harbert Fund Advisors sold 177,815 Fennec Pharmaceuticals shares in Q4 2025, an estimated $1.66M.
Harbert Fund Advisors first reported a position in Fennec Pharmaceuticals in Q2 2021 and held it in 18 quarters.
Harbert Fund Advisors's Fennec Pharmaceuticals position peaked at $5.24M in Q4 2023.
96 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2025.

Based on Harbert Fund Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.